H01 for adults with lung scarring (SOLIS study)
Part of Lungs & breathing clinical trials.
This study tests an oral medication (H01/hymecromone) to see if it can help people with progressive lung scarring (ILD). It lasts about 12 to 24 weeks and requires good lung function without needing oxygen at rest.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have a diagnosis of Idiopathic Pulmonary Fibrosis or another progressive lung scarring disease.
- Your lung function tests (DLCO and FVC) must be above certain minimum levels (DLCO >30% and FVC >45% of normal).
- If you can become pregnant or father a child, you must agree to use effective contraception during the study.
- You cannot be on the lung transplant list, need oxygen at rest, or have certain other medical conditions like liver disease or celiac disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who are being seen for lung scarring (also called ILD) and compares them with family members without lung scarring. It helps researchers better understand how this condition changes over time and what to look for in the future.
This study is for people with a specific type of lung scarring (not IPF) to understand how the disease progresses. Researchers will collect detailed health information, imaging, and blood samples to learn more about the condition.
This study is testing a new way to track lung scarring (fibrosis) over time in people with conditions like IPF, other fibrotic lung diseases, or early signs of scarring. It might help doctors understand how the disease changes.
This study tests an experimental pill called SYH2059 for people with IPF, a condition that causes lung scarring and makes breathing harder. The goal is to see if the pill is safe and can help slow down the disease.
This study follows patients with chronic lung scarring (fibrosing interstitial lung disease) who are in the intensive care unit for severe breathing failure. It aims to better understand their condition and care, which may help improve future treatments.
This trial tests an investigational drug called LAM-001 for people who have pulmonary hypertension (high blood pressure in the lungs) along with a type of lung disease called interstitial lung disease. The drug may help improve symptoms and daily function. This study will see if the drug is safe and helpful for this condition.
Hear when a new Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.